HEMODYNAMICS, TOLERABILITY, AND PHARMACOKINETICS OF LINSIDOMINE (SIN-1) INFUSION DURING THE ACUTE-PHASE OF UNCOMPLICATED MYOCARDIAL-INFARCTION

被引:7
作者
FOUCHERLAVERGNE, A
KOLSKY, H
SPREUXVAROQUAUX, O
DELONCA, J
BEAUFILS, P
机构
[1] HOP LARIBOISIERE,DEPT CARDIOL,2 RUE AMBROISE PARE,F-75475 PARIS 10,FRANCE
[2] LABS HOECHST,PARIS,FRANCE
[3] GRP HOSP ANDRE MIGNOT,HOP VERSAILLES,DEPT PHARMACOL,LE CHESNAY,FRANCE
关键词
ACUTE CORONARY SYNDROME; MYOCARDIAL INFARCTION; LINSIDOMINE; VASODILATORS;
D O I
10.1097/00005344-199312000-00001
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
To determine a dose regimen and evaluate the hemodynamic effects of linsidomine administered by continuous intravenous (i.v.) infusion, 10 patients were studied during the acute phase of uncomplicated myocardial infarction (MI). Systolic, diastolic, and mean (SBP, DBP, MBP) systemic blood pressure and heart rate (HR) were measured noninvasively. Pulmonary artery pressures were monitored after insertion of a Swan-Ganz catheter, which also enabled measurement of cardiac output (CO) and cardiac index (CI) by thermodilution. After baseline hemodynamic values (period A) were determined, linsidomine (SIN-1) was infused at a rate of 0.8 mg/h and subsequently adjusted to obtain a 10% decrease in MBP from its baseline value (period B). The infusion was then continued for 3 h at a constant rate (period C), and pressures were monitored for 1 h after the infusion was discontinued (period D). There were no significant changes in systemic or pulmonary arterial pressures or in HR between period B and period C. In contrast, CI decreased moderately (p < 0.05), with no clinical consequences. Return to baseline hemodynamics was obtained at the end of period D. Our findings indicate that continuous i. v. administration of SIN-1 (at a mean flow rate of 1 mg/h) is well tolerated and appears to be suitable for use in acute coronary syndromes.
引用
收藏
页码:779 / 784
页数:6
相关论文
共 21 条
[11]   EFFECT OF MOLSIDOMINE ON EXVIVO PLATELET-AGGREGATION AND PLASMA GUANOSINE 3'-5'-CYCLIC MONOPHOSPHATE LEVELS IN HEALTHY-VOLUNTEERS [J].
KARRENBROCK, B ;
HEIM, JM ;
GERZER, R .
KLINISCHE WOCHENSCHRIFT, 1990, 68 (04) :213-217
[12]  
KIPSHIDZE NN, 1986, ISCHEMIC HEART DISEA, P128
[13]  
KUKOVETZ WR, 1987, PATHOL BIOL, V35, P260
[14]  
MEINERTZ T, 1986, ISCHEMIC HEART DISEA, P43
[15]   VASORELAXING ACTIONS OF MOLSIDOMINE AND ITS METABOLITES, IN COMPARISON WITH NITROGLYCERIN [J].
MURAMATSU, I ;
FUJII, K ;
SAKAKIBARA, Y ;
FUJIWARA, M .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1983, 61 (09) :1071-1078
[16]  
NISHIKAWA M, 1982, J PHARMACOL EXP THER, V220, P183
[17]   ACTIVE AND PASSIVE CHANGES IN CORONARY DIAMETER AFTER VASODILATION WITH SIN-1, THE ACTIVE METABOLITE OF MOLSIDOMINE [J].
SCHULZ, W ;
KOBER, G ;
BERNAUER, R ;
KALTENBACH, M .
AMERICAN HEART JOURNAL, 1985, 109 (03) :694-699
[18]   LONG-ACTING CORONARY VASODILATORY ACTION OF THE MOLSIDOMINE METABOLITE SIN-I - A QUANTITATIVE ANGIOGRAPHIC STUDY [J].
SERRUYS, PW ;
DECKERS, JW ;
LUIJTEN, HE ;
REIBER, JHC ;
TIJSSEN, JGP ;
CHADHA, D ;
HUGENHOLTZ, PG .
EUROPEAN HEART JOURNAL, 1987, 8 (03) :263-270
[19]  
SHUGUANG L, 1985, AM J CARDIOL, V56, P742
[20]   THE NEW LONG-ACTING CORONARY-ARTERY DILATOR MOLSIDOMINE AND ITS METABOLITE SIN-1 [J].
SOBOLSKI, J ;
VANDERMOTEN, P ;
STOUPEL, E ;
BERKENBOOM, G ;
DEGRE, S .
AMERICAN HEART JOURNAL, 1985, 109 (03) :700-703